PROGNOSIS

hPG80: a Prognostic Biomarker

Prognostic biomarkers play a crucial role in the clinical practice because it not only detects the presence of cancer but also allow stratification of patients in terms of predicting the outcome of the disease.

hPG80: a Prognostic Biomarker in at least 4 Different Cancers

In 4 published studies, we explored the prognosis value of hPG80 in metastatic renal cell carcinoma (mRCC), hepatocellular carcinoma (HCC), breast cancer and glioblastoma.

Kohli et al. 2021, Dupuy et al. 2022; Prieur et al. 2023; Doucet et al. 2023

These studies highlighted the association between high hPG80 levels and worse outcomes (overall survival/progression-free-survival).

High hPG80 Levels Associated with Worse Clinical Outcome

Below are the results obtained in mRCC, where we conducted our initial proof of concept study, as well as in HCC.

Metastatic Renal Cell Carcinoma

Kaplan-Meier analysis of overall survival (OS) in 96 metastatic renal cell carcinoma patients managed with local or systemic treatments, including molecular targeted agents. Patients were stratified into two groups depending on hPG80 levels.

mOS: median overall survival; HR: Hazard Ratio, 95%CI: 95% Confidence Interval.

Adapted from Kohli et al. Cancers 2021

Hepatocellular Carcinoma

Kaplan-Meier analysis of overall survival (OS) in 168 hepatocellular carcinoma patients managed with local or systemic treatments, including molecular targeted agents. Patients were stratified into two groups depending on hPG80 levels.

mOS: median overall survival; NR: not reached, HR: Hazard Ratio, 95%CI: 95% Confidence Interval.